Maveral (Fluvoxamine Maleate)

Fluvoxamine selectively blocks the serotonin transporter (SERT), preventing reuptake of serotonin into presynaptic neurons. This raises serotonin levels in the synaptic cleft, improving neurotransmission in pathways that regulate mood, anxiety, and compulsive behaviors.

The appropriate dose of Maveral is individualized by the prescribing clinician based on the patient’s diagnosis, severity of symptoms, age, liver function, and response to therapy. Dosage adjustments may be required for hepatic impairment or drug interactions.

Safety data for fluvoxamine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against uncertain risks and consider alternative therapies when possible. Breastfeeding mothers should discuss potential infant exposure with their healthcare provider.

To request Maveral, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maveral (fluvoxamine) and sertraline belong to the same SSRI class but differ in pharmacokinetic profiles and specific drug‑interaction potentials. Fluvoxamine has a stronger inhibition of certain cytochrome P450 enzymes, which may increase interactions, while sertraline is generally considered to have fewer metabolic interactions.

Maveral should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Maveral is taken orally, usually once daily in the evening, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

The most serious risks include the potential for serotonin syndrome when combined with other serotonergic agents, emergence of suicidal thoughts or behaviors, especially during early treatment, and rare severe allergic reactions such as anaphylaxis.

Maveral is contraindicated in patients who are currently taking monoamine oxidase inhibitors, have a known hypersensitivity to fluvoxamine or any excipients, or have a history of severe serotonin syndrome. Caution is also advised for individuals with significant hepatic impairment.